CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 13:10:40 2024-06-03 EDT | ||
| 1.935 EUR | -1.53% |
|
| Current month | +1.02% | ||
| 1 month | +91.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 1.935 | -1.53% |
| 24-05-31 | 1.965 | +8.86% |
| 24-05-30 | 1.805 | +1.98% |
| 24-05-29 | 1.77 | -3.01% |
| 24-05-28 | 1.825 | -2.67% |
Real-time Borsa Italiana
Last update June 03, 2024 at 01:10 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F43953 | |
| ISIN | DE000VM8AEB1 |
| Date issued | 2024-02-06 |
| Strike | 790.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.11 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.3 € |
|---|---|
| Lowest since issue | 0.389 € |
| Spread | 0.125 € |
| Spread % | 6.11% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- F43953 Certificat
